NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Corvus Pharmaceuticals, Inc. (CRVS) Stock Analysis

Corvus Pharmaceuticals, Inc. (CRVS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CRVS

$14.39

−$0.26 (−1.77%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRVS with… →

CRVS Key Statistics

As of Sep 4, 2026
Trading
Open
$14.34
Previous Close
$14.65
Day's Range
14.34–14.74
52-Week Range
5.64–26.95
Volume
626.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.86
Valuation
Market Cap
$1.21B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.64
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$15.28M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
84.12M
1-Year Return
+151.13%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.04M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRVS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+86.88%
2025+43.93%
2024+203.98%
2023+107.06%
2022−64.73%
2021−32.30%
2020−34.56%
2019+48.23%
2018−64.58%
2017−27.55%
2016 (partial year)+3.70%

As of September 4, 2026.

CRVS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$15.28M—
2024$0.00−$62.29M—
2023$0.00−$27.03M—
2022$0.00−$41.31M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$42.97M−$15.28M—
2024$0.00—−$27.55M−$62.29M—
2023$0.00—−$23.41M−$27.03M—
2022$0.00—−$32.57M−$41.31M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRVS Valuation vs Biotechnology Median

Median of 656 stocks
MetricCRVSBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Corvus Pharmaceuticals, Inc. (CRVS) is capitalised at $1.21B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 37 employees.

The 52-week range on file runs from $5.64 to $26.95. The most recent close on file for CRVS is $14.39, dated September 4, 2026. That is −$0.26 (−1.77%) against the previous close. The latest close sits 155.14% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $15.28M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.64.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.86. Daily returns over the trailing 10 years annualize to a volatility of 111.24%. The trailing one-year price return is +151.13%. Measured over 10 years, that is +0.57% a year compounded.

Growth & Income

No dividend is on file for CRVS.

So far in 2026 the price is +86.88%. The strongest complete calendar year on file is 2024 at +203.98%; the weakest is 2022 at −64.73%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Corvus Pharmaceuticals, Inc. (CRVS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Corvus Pharmaceuticals, Inc. CRVS $1.21B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Corvus Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Visit website →